Cancer BiologybioRxivPreprint
ACB1801 enhances tumor immunogenicity by targeting glycolysis/ferroptosis vulnerability and activating STAT1-signaling to overcome anti-PD-1 resistance in MSS colorectal cancer
Ruize Gao, Kris Van Moer, Coralie Pulido…·Bassam Janji
ACB1801 enhances anti-PD-1 therapy efficacy in MSS CRC by reprogramming the TME through metabolic reprogramming and STAT1 signaling activation.
DOI 10.64898/2026.02.23.707369